Dlh Holdings Corp. · NASDAQ:DLHC
Dlh — Noble Capital's 18th Annual Microcap Investor Conference (April 2022)
18 slides from Dlh's conference presentation, Apr 20, 2022
Slide 1: Noble Capital's 18th Annual Microcap Investor Conference
Your Mission is Our Passion Noble Capital’s 18th Annual Microcap Investor Conference APRIL 20, 2022
Slide 2: Forward-looking statements
Forward-looking statements “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future
Slide 3: DLH: Delivering health and readiness solutions through innovation
DLH: Delivering health and readiness solutions through innovation Solving complex problems faced by Leveraging digital transformation, Premier credentials and certifications, Federal civilian and military customers AI/ML, data analytics, secure cloud world-class workforce of skilled computing, model
Slide 4: DLH addressable markets aligned with priority budget initiatives
DLH addressable markets aligned with priority budget initiatives Addressable spending focused on high-impact technology and subject matter expertise in chosen markets to enhance mission outcomes FEDERAL BUDGET AUTHORITY TOP 3 DLH CUSTOMERS BY REVENUE SECURE DATA SYSTEM MODERNIZATION & ANALYTICS & SE
Slide 5: Enhanced capabilities inform a bolstered new business pipeline
Enhanced capabilities inform a bolstered new business pipeline ~$2B pipeline 1 Shifting care to secure technology needs PROPOSAL IN PROCESS 2 Public health infrastructure rebuilding ~$800M 3 Mission-focused modernization and security 4 Best in Class contracts Increased supplemental services – behavi
Slide 6: Implementation of Five-Year Strategy Drove Increased Value
Implementation of Five-Year Strategy Drove Increased Value 2016 – 2021 12.0% EBITDA MARGIN PERCENTAGE BOOZ ALLEN 11.0% LEIDOS PRIMARY FOCUS ON MARKET ACCESS, ICF CACI 10.0% SECONDARY EMPHASIS ON CAPABILITIES SAIC ORGANIC CAGR OF 7% OVER FIVE-YEAR 9.0% MANTECH TIME PERIOD 8.0% MEDICAL EXPANDED ESTABL
Slide 7: Path Ahead – The Next Phase in our Corporate Journey
Path Ahead – The Next Phase in our Corporate Journey Strong senior lending group, anticipated operating cash flow and low capex requirements, provide meaningful flexibility in financing potential future acquisitions Deepen our capabilities Prioritize innovation and technology credentials and service
Slide 8: Financial Highlights
> Financial Highlights
Slide 9: Performance Trends
Performance Trends $ millions $300 12% 10.30% 9.80% $250 10% 8.70% 8.30% $200 7.30% 8% $150 5.30% 6% 4.00% $246.1 $100 $209.2 4% $160.4 0.70% 1.50% $133.2 $115.7 $50 2% $85.6 $60.5 $65.3 $53.5 $0 0% FY13 FY14 FY15 FY16 FY17 FY18 FY19 F720 FY21 Revenue EBITDA Margin A reconciliation of net income to
Slide 10: Debt Position and Outlook
Debt Position and Outlook Strong cash flow anticipated to fund additional de-levering in FY2022, with a target YE debt position of between $25 and $28 million. $80,000 3 2.67 2.8 $70,000 2.5 IBA $60,000 Acquisition Total Leverage Ratio 1.81 2 (In thousands) 09/30/19 09/30/20 09/30/21 12/31/21 Net De
Slide 11: Recent Financials – FY2022 Q1 (period ending 12/31/2021)
Recent Financials – FY2022 Q1 (period ending 12/31/2021) Revenue EBITDA $ millions $ millions $160 $152.8 $14 $13.2 $12 $120 $91.1 $10 $6.3 $8 $80 $6 $40 $4 $6.9 $57.9 $61.7 $5.7 $2 $0 $0 FY21 Q1 FY22 Q1 FY21 Q1 FY22 Q1 Sustaining Business FEMA Sustaining Business FEMA FY22Q1 reflects the impact fro
Slide 12: Appendix
> Appendix
Slide 13: Non-GAAP Reconciliations
Appendix Non-GAAP Reconciliations This document contains non-GAAP financial information including EBITDA and EBITDA as a percentage of revenue. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of
Slide 14: FY2022 Q1 EBITDA Reconciliation
FY2022 Q1 EBITDA Reconciliation Three Months Ended December 31, (amount in thousands) 2021 2020 Change Net (loss)/income $ 7,804 $ 1,814 $ 5,990 (i) Interest expense/other (income) 672 1,080 (408) (ii) (Benefit)/provision for taxes 2,743 741 2,002 (iii) Depreciation and amortization 1,985 2,062 (77)
Slide 15: Reconciliation of FY2022 Q1 FEMA Business
Reconciliation of FY2022 Q1 FEMA Business Three Months Ended December 31, (In thousands) Ref 2021 2020 Change Revenue Ref (a): Revenue for the Company’s remaining contract portfolio less the FEMA task orders represents our consolidated revenues less the revenues generated Total enterprise $ 152,801
Slide 16: Trending EBITDA Reconciliation
Trending EBITDA Reconciliation Twelve Months Ended September 30, (amount in thousands) 2013 2014 2015 2016 2017 2018 2019 2020 2021 Net (loss)/income $ (159) $ 5,357 $ 8,728 $ 3,384 $ 3,288 $ 1,836 $ 5,324 $ 7,114 $ 10,145 (i) Interest expense/other (income) 407 4 (744) 823 1,228 1,116 2,473 3,441 3
Slide 17: Reconciliation of Leverage Ratio
Reconciliation of Leverage Ratio IBA ACQUISITION (amount in thousands) 09/30/19 09/30/20 09/30/21 12/31/21 Term Loan $ 56,000 $ 70,000 $ 46,750 $ 42,875 Revolving Credit Loan - - - - Letters of Credit 1,745 1,990 2,095 2,095 Total Funded Debt $ 57,745 $ 71,990 $ 48,845 $ 44,970 Consolidated EBITDA $
Slide 18: About DLH
About DLH DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers
DLH Holdings — Noble Capital's 18th Annual Microcap Investor Conference (April 2022) on 6ix